Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

被引：1

作者：

Weinbergerova, Barbora ^{[1
,2
]}

Mayer, Jiri ^{[1
,2
]}

Kabut, Tomas ^{[1
,2
]}

Sperr, Wolfgang R. ^{[3
,4
]}

Stevkova, Jana ^{[5
]}

Jonasova, Anna ^{[6
]}

Cernan, Martin ^{[7
,8
]}

Herndlhofer, Susanne ^{[3
]}

Oravcova, Iveta ^{[9
,10
]}

Sramek, Jiri ^{[11
]}

Novak, Jan ^{[12
,13
]}

Stepanova, Radka ^{[14
]}

Szotkowski, Tomas ^{[7
,8
]}

Drgona, Lubos ^{[9
,10
]}

Zak, Pavel ^{[5
]}

Valent, Peter ^{[3
,4
]}

机构：

[1] Masaryk Univ, Dept Internal Med Hematol & Oncol, Jihlavska 20, Brno 62500, Czech Republic

[2] Univ Hosp Brno, Jihlavska 20, Brno 62500, Czech Republic

[3] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria

[4] Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Vienna, Austria

[5] Univ Hosp Hradec Kralove, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[6] Charles Univ Prague, Gen Hosp, Med Dept, Hematol, Prague, Czech Republic

[7] Palacky Univ Olomouc, Fac Med & Dent, Dept Hemato Oncol, Olomouc, Czech Republic

[8] Univ Hosp Olomouc, Olomouc, Czech Republic

[9] Comenius Univ, Dept Oncohematol, Bratislava, Slovakia

[10] Natl Canc Inst, Bratislava, Slovakia

[11] Univ Hosp Plzen, Dept Haematol & Oncol, Plzen, Czech Republic

[12] Charles Univ Prague, Fac Med 3, Dept Haematol, Prague, Czech Republic

[13] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic

[14] Masaryk Univ, Fac Med, Ctr Excellence CREAT, Brno, Czech Republic

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 05期

关键词：

acute myeloid leukaemia; antifungal prophylaxis; fungal infection; venetoclax and azacitidine;

D O I：

10.1111/bjh.19670

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.

引用

页码：1746 / 1750

页数：5

共 50 条

[21] Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia
Gibson, Amber
Dickson, Samantha
McCall, David
Garcia, Miriam
Connors, Jeremy
He, Jiasen
Roth, Michael
Nunez, Cesar
Cuglievan, Branko
PEDIATRIC BLOOD & CANCER, 2024,
[22] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
Short, Nicholas J.
Sedarati, Farhad
Zhao, Dan
Tsukurov, Olga
Friedlander, Sharon
Faller, Douglas V.
BLOOD, 2020, 136
[23] A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.
Gu, Chengyuan
Wang, Ruju
Kang, Huizhu
He, Xuefeng
Chen, Jun
Lin, Zhihong
Liu, Yuejun
Yang, Ting
Wu, Depei
Han, Yue
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[24] Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax plus Hypomethylating Agent
Gangat, Naseema
Elbeih, Azeem
Ghosoun, Nour
Mccullough, Kristen
Aperna, Fnu
Johnson, Isla M.
Abdelmagid, Maymona
Al-Kali, Aref
Alkhateeb, Hassan B.
Begna, Kebede H.
Elliott, Michelle
Mangaonkar, Abhishek
Matin, Aasiya
Saliba, Antoine N.
Torghabeh, Mehrdad Hefazi
Litzow, Mark R.
Hogan, William
Shah, Mithun
Patnaik, Mrinal M.
Pardanani, Animesh
Badar, Talha
Murthy, Hemant
Foran, James
Palmer, Jeanne
Sproat, Lisa
Khera, Nandita
Yi, Cecilia Arana
Yates, Samuel
Sneider, Abigail
Dworkin, Emily
Patel, Anand A.
Bazinet, Alexandre
Senapati, Jayastu
Bataller, Alex
Dinardo, Courtney
Kadia, Tapan
Tefferi, Ayalew
AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (02) : 260 - 271
[25] Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features
Gutman, Jonathan A.
Winters, Amanda
Amaya, Maria L.
McMahon, Christine M.
Schowinsky, Jeffrey
Abbott, Diana
Hammes, Andrew
Pei, Shanshan
Stevens, Brett M.
Jordan, Craig T.
Smith, Clayton
Pollyea, Daniel A.
BLOOD, 2020, 136
[26] Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.
Ravandi, Farhad
Carraway, Hetty E.
Taningco, Lilia
Laille, Eric
Gong, Jing
Prebet, Thomas
De Menezes, Daniel Lopes
Wei, Andrew H.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[27] Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?
Guarana, Mariana
Nucci, Marcio
LEUKEMIA RESEARCH, 2023, 131
[28] Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment
Ikezoe, Takayuki
Usuki, Kensuke
Aida, Kensuke
Hatayama, Tomoyoshi
Shirahase, Toru
Yamauchi, Takahiro
CANCER SCIENCE, 2023, 114 (03) : 1037 - 1044
[29] Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.
De Botton, Stephane
Montesinos, Pau
Polo, Susana Vives
Zarzycka, Ewa
Wang, Jianxiang
Riva, Marta
Heuser, Michael
Calado, Rodrigo T.
Schuh, Andre C.
Yeh, Su-Peng
Hui, Jianan
Gianolio, Diego A.
Patel, Prapti Arvind
Recher, Christian
Dohner, Hartmut
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30] Updated efficacy and safety data from the AGILE study in patients with newly-diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine
Heuser, M.
Montesinos, P.
Vives, Polo S.
Zarzycka, E.
Wang, J.
Riva, M.
Calado, R. T.
Schuh, A. C.
Yeh, S. -P
Hui, J.
Gianolio, D. A.
Patel, P.
Recher, C.
de Botton, S.
Doehner, H.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 95 - 95

← 1 2 3 4 5 →